Latest news with #BauschHealth
Business Recorder
15 hours ago
- Business
- Business Recorder
TSX dips on Middle East conflict concerns
Canada's main stock index fell on Thursday, as caution prevailed over heightened tensions in the Middle East and the United States' possible involvement in the conflict. The S&P/TSX composite index was down 0.2% at 26,510.63 points. Israel bombed nuclear targets in Iran on Thursday and Iranian missiles hit an Israeli hospital overnight, as the week-old air war escalated with no sign yet of an off-ramp. President Donald Trump, meanwhile, has kept the world guessing about whether the U.S. would join Israel in the airstrikes. 'There is potential for the U.S. to become more involved, which is not desirable, and I think that the overall escalation of the conflict period is definitely weighing down global sentiment,' said Shiraz Ahmed, founder & CEO at Sartorial Wealth Inc. The conflict has impacted oil prices, which rose on the day and boosted the energy sector by 0.6%. On the flip side, healthcare stocks were the biggest decliner, down 0.9%, with pharmaceutical firm Bausch Health companies falling 2.4%. Information and Technology fell 0.7%. Materials dropped 0.6% as gold prices held steady while copper hit a near one-week low. Most other base metals also declined, pressured by a stronger U.S. dollar. GOL/MET/L The benchmark index shed most of its gains to end almost flat on Wednesday after Federal Reserve Chair Jerome Powell said inflation in goods prices is expected to go up over the summer as Trump's tariffs work their way to consumers. Also on Wednesday, Bank of Canada Governor Tiff Macklem said that the prospect of a new Canada-U.S. trade deal offers hope that tariffs will be removed, but cautioned that inflation could rise if tariffs remain in place. Trump and Canada's Prime Minister Mark Carney this week agreed to reach a trade deal between the two countries in 30 days. Among individual stocks, food retailer Empire Company Ltd jumped 5.4% to the top of TSX after reporting quarterly profit above the analyst's estimates. Trade volumes are expected to remain thin as U.S. markets are closed for a public holiday.
Business Insider
2 days ago
- Business
- Business Insider
Bausch Health director Paulson buys $21.2M in common stock
In a regulatory filing, Bausch Health (BHC) disclosed that its director John Paulson bought 3.56M shares of common stock on June 13th in a total transaction size of $21.2M. Shares are up 4% afterhours at $5.97. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
6 days ago
- Business
- Yahoo
Bausch Health (BHC) Jumps 8.5% as Exec Hikes Stake; Subsidiaries Raise Over $3-Billion Fresh Funds
We recently published a list of . In this article, we are going to take a look at where Bausch Health Companies Inc. (NYSE:BHC) stands against other best-performing stocks of Friday. Bausch Health extended its winning streak to a sixth consecutive day on Friday, ending 8.53 percent higher at $5.98 apiece after one of its directors acquired $15 million worth of shares in the company. In a regulatory filing on Thursday, Bausch Health Companies Inc. (NYSE:BHC) said that its director, John Paulson, acquired nearly 2.79 million new shares through his company, Paulson Capital Inc., at a price of $5.05 to $5.47 apiece. A series of pharmaceutical and medical products in a warehouse, displaying the range of products available. No reason was divulged regarding the transaction, but investors may have taken the acquisition as a cue to bargain-hunt on its shares. Paulson's acquisition followed the listed firm's regulatory filing earlier this week that one of its direct subsidiaries and two indirect subsidiaries are planning to raise more than $3 billion in fresh funds through the issuance of a loan facility and revolving credit facility. On Tuesday, the listed firm's direct arm, Bausch + Lomb Corporation, launched a 600-million euro ($693 million) senior notes offering on Tuesday. This was on top of another $3 billion being raised by two indirect subsidiaries through a term B loan facility amounting to $2.2 billion and a revolving credit facility worth $800 million. Bausch Health Companies Inc. (NYSE:BHC) said funds from the fundraising program will be used for the repayment of its direct subsidiary's existing revolving credit facility, refinancing of term loans due 2027, and paying other fees and expenses, as well as general corporate purposes. While we acknowledge the potential of BHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
LAVAL, QC / / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Kennedy, et al. (Case No. 25-cv- 00091), denied Norwich's motion for a preliminary injunction treated as a motion for summary judgment in its lawsuit against the U.S. Food and Drug Administration (FDA). Norwich had asked the District Court for a judgment declaring the FDA's decision to issue tentative approval for Norwich's Abbreviated New Drug Application (ANDA) for XIFAXAN® (rifaximin) 550 mg and failure to determine Teva Pharmaceuticals USA, Inc. (Teva) had forfeited its 180-day exclusivity were arbitrary, capricious, and contrary to law. Norwich sought an injunction directing the FDA to immediately grant Final Approval to Norwich's ANDA for XIFAXAN® (rifaximin) 550 mg. Norwich argued that if upheld, FDA's determination will prohibit Norwich from marketing those products until at least June 29, 2028, assuming Teva launches its rifaximin product in January 2028. Today, the District Court denied Norwich's motion and granted summary judgment in favor of the FDA, Salix, and Teva, and closed the case. "We are pleased with the ruling issued today by the U.S. District Court. We will persist in advocating for the well-being of patients who have greatly benefited from sustained access to XIFAXAN," said Thomas J. Appio, CEO of Bausch Health. Management will release first quarter financial results after market close on Wednesday, April 30, 2025, followed by a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit and connect with us on LinkedIn. Forward-looking Statements This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. Investor Contact:Garen Sarafianir@ 281-6642 (toll free) Media Contact:Katie 569-3692 SOURCE: Bausch Health Companies Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
1 Undervalued TSX Stock Down 56% to Buy and Hold
Written by Amy Legate-Wolfe at The Motley Fool Canada Sometimes, the best deals pop up when things look a bit gloomy. Bausch Health (TSX:BHC) on the TSX might be one of those chances. It's faced some tough times lately, but if you look at how the company is doing now and its money situation, there could be potential for investors who are thinking long term. As of writing, the TSX stock is now trading at around $6. That's quite a drop from its highest point in the last year, which was $13.74. That's a decrease of about 56%! Because of this drop, the TSX stock's total value on the stock market is around $2.2 billion. However, if we look at the company's earnings report for the last three months of 2024, things look a little brighter. Bausch Health reported revenue of $3.63 billion. That was actually a bit higher than what analysts were expecting, which was $3.60 billion. The earnings per share (EPS) matched what analysts predicted at $1.62. Looking at the whole year, the TSX stock's total revenue was $13.85 billion. However, it reported a net loss of $66.19 million for the year, which means a loss of $0.18 per share. Even with this loss, the company managed to generate a good amount of free cash flow, $1.81 billion, to be exact. This shows that even though it had a net loss, the TSX stock is still good at bringing in cash. Bausch Health has different parts of its business. These include Salix, Solta Medical, and Bausch + Lomb. Having these different segments helps the TSX stock spread out its risks. If one area isn't doing so well, the others might help balance things out. Looking at some of the TSX stock's financial numbers, the gross profit margin is pretty high at 71.10%. The operating margin, which is the profit after operating expenses, is also decent at 19.40%. The profit margin, which is the actual profit after all expenses, is down 0.48%. However, the earnings before interest, taxes, depreciation, and amortization (EBITDA) is a healthy 32.56%. These numbers suggest that Bausch Health is actually pretty efficient and profitable in its operations before taking into account things like debt and taxes. Now, let's talk about the debt. The company has a total debt of $31.42 billion. Compared to its cash and equivalents of $1.70 billion, that's a net debt of $29.72 billion. That's a significant amount of debt, which is definitely a concern for investors. However, the fact that the TSX stock consistently generates a good amount of free cash flow gives some comfort that it should be able to handle its debt payments. What do the experts think? Well, analysts seem cautiously optimistic. The average price target from six analysts is $8.58. That suggests the stock price could go up from where it is now. Also, the company's forward price-to-earnings (P/E) ratio is at 0.99. A P/E ratio that low can indicate that the stock might be undervalued compared to how much money it's expected to make. So, to sum it up, Bausch Health definitely has some big challenges, especially with that high level of debt and the recent drop in its stock price. However, the TSX stock is still bringing in a lot of revenue, seems to be operating efficiently, and has different business areas. This could make a case for investors who are willing to think long term. As always, though, if you're thinking about investing, it's super important to do your own research and figure out how much risk you're comfortable with before making any decisions. The post 1 Undervalued TSX Stock Down 56% to Buy and Hold appeared first on The Motley Fool Canada. Before you buy stock in Bausch Health Companies, consider this: The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Bausch Health Companies wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $20,697.16!* Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*. See the Top Stocks * Returns as of 3/20/25 More reading Best Canadian Stocks to Buy in 2025 Market Volatility Toolkit 4 Secrets of TFSA Millionaires Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 2025
